# Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

> clinical trial · VERIFIED · 2026-08-07

Status: RECRUITING · Sponsor: Eli Lilly and Company · Condition: Carcinoma, Non-Small-Cell Lung

- Company: Eli Lilly and Company
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT06890598

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.